Business

Kristin Comella, U.S. Stem Cell’s CSO, Co-Authors Scientific Paper on Irradiation-Induced Gland Damage Published in the International Medical Case Reports Journal

Kristin Comella, U.S. Stem Cell’s CSO, Co-Authors Scientific Paper on Irradiation-Induced Gland Damage Published in the International Medical Case Reports Journal.

articleU.s. Stem Cell, Inc.August 17, 20174/company/us-stem-cell-inc/news/kristin-comella-us-stem-cells-cso-co-authors-scientific-paper-on-irradiation-induced-gland-damage-published-in-the-international-medical-case-reports-journal
Kristin Comella, U.S. Stem Cell’s CSO, Co-Authors Scientific Paper on Irradiation-Induced Gland Damage Published in the International Medical Case Reports Journal

About this update from U.s. Stem Cell, Inc.

[{"type":"text","content":"SUNRISE, FL / ACCESSWIRE / August 17, 2017 / U.S. Stem Cell, Inc. (OTCQB: USRM). A scientific paper about intraglandular injection for the treatment of irradiation-induced gland damage post cancer co-authored by Kristin Comella, Chief Science Officer at U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, was published in the August 2017 issue of the International Medical Case Reports Journal. Comella is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapin's list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Comella has pioneered stem cell therapies from various sources, including cord blood, bone marrow, muscle, and adipose. Entitled, \"First-in-man intraglandular implantation of stromal vascular fraction and adipose-derived stem cells plus platelet-rich plasma in irradiation-induced gland damage: a case study,\" the scientific paper was co-authored by Kristin Comella and Walter Bell. Below is a link and abstract to the paper: https://www.dovepress.com/articles.php?article_id=34273Background: Stromal vascular fraction (SVF) is a mixture of cells which can be isolated from a mini-lipoaspirate of fat tissue. Platelet-rich plasma (PRP) is a mixture of growth factors and other nutrients which can be obtained from peripheral blood. Adipose-derived stem/stromal cells (ADSCs) can be isolated from fat tissue and expanded in culture. The SVF includes a variety of different cells such as ADSCs, pericytes, endothelial/progenitor cells, and a mix of different growth factors. The adipocytes (fat cells) can be removed via centrifugation. Here, we describe the rationale and, to our knowledge, the first clinical implementation of SVF and PRP followed by repeat dosing of culture-expanded ADSCs into a patient with severe xerostomia post irradiation.Methods: Approximately 120 mLs of adipose tissue was removed via mini-lipoaspirate procedure under local anesthetic. The SVF was prepared from half of the fat and resuspended in PRP. The mixture was delivered via ultrasound directly into the submandibular and parotid glands on both the right and left sides. The remaining 60 mLs ...

More updates from U.s. Stem Cell, Inc.